

Bringing clinical and research data together for the benefit of patients

SPHN | Swiss Personalized Health Network PHRT | Personalized Health and Related Technologies

Dr. Thomas Geiger, Managing Director SPHN Prof. Bernd Wollscheid, Chair PHRT Executive Committee

SPHN | Swiss Personalized Health Network www.sphn.ch | nds@sphn


PHRT | Personalized Health and Related Technologies www.sfa-phrt.ch | phrt-office@ethz.ch








Thinking end-to-end...



Strategic Focus Area Personalized Health and Related Technologies

Established SPHN data infrastructures and services





3

(HIT-STAG)





swissuniversities

luzerner kantonsspital

Coordinate university hospital research IT

- **Semantic Working Groups**
 - Harmonized description of health data

Data Governance Working Group Harmonized templates and processes

Hospital IT Strategy Alignment Group

- Principles for responsible sharing of health data
- **ELSI Advisory Group**

The power is in the network

Strategic Focus Area Personalized Health nd Related Technologies

DATA

Insel

USZ Universitäts

UKBB

- University Hospital Basel

health 2030

Gruppe AG

Zurich

Medizin Schwe Médecine

Personalized Health Alli

KSA

Basel-Zurich

SW

WINSELSPITAL

ehealthsuisse

Basel <

Bern

SAKK

WISS SCHOOL O

KSB

🔼 SDSC

+ 000 USB

SENSA

ATA

HUG

SSPH+

SIB

Lausanne



ssethics


BIOBANKIN



From Health Data Discoverability...

Federated Query System

> 710'000 patients (general consent), 5 hospitals
> 699'000'000 data elements: Demographics, Diagnoses, Procedures, Medication, Laboratory tests and values




... to Federated Data Exploration

Data Exploration & Analysis System (2025)



- Full SPHN Dataset (>165 clinical parameters)
- All patients with General Consent since 2018 from 6 hospitals
- Value distribution and survival curves of patient cohorts
- Fully privacy preserving, powered by TUNE INSIGHT







6



Bringing it all together - National Data Streams (NDS)



NDS - reusable, meaningful and growing Knowledge Graphs



31.10.24

Strategic Focus Area

Personalized Health

and Related Technologies



8

Personalized

Health

SPHN

Network





SPHN-PHRT National Data Streams



Personalized, datadriven prediction and assessment of infectionrelated outcomes in Swiss ICUs (IICU)

Main Pls: Prof. Dr. Adrian Egli (UZH) & Prof. Dr. Catherine Jutzeler (ETHZ)

Duration: 01.09.2022 -31.08.2025 (36 months) Award: CHF 5 Mio

Lay summary I More information



Swiss Personalized Oncology National Data Stream (SPO-NDS)

Main Pls: Prof. Dr. Olivier Michielin (CHUV) & Prof. Dr. Bernd Bodenmiller (ETHZ)

Duration: 01.09.2022 -31.08.2025 (36 months) Award: CHF 5 Mio

Lay summary | More information

SwissPed Health

Pediatric personalized research network Switzerland (SwissPedHealth) - a Joint Pediatric National Data Stream

Main PIs: Prof. Dr. Luregn Schlapbach (University Children's Hospital Zurich) & Prof. Dr. Julia Vogt (ETHZ)

Duration: 01.09.2022 -31.08.2025 (36 months) Award: CHF 5 Mio

Lay summary | More information



LUCID, Low Value of Care in Hospitalized Patients, a National Data Stream on Quality of Care in Swiss university hospitals

Main Pls: Dr. Marie Méan (CHUV) & Dr. Guillaume Obozinski (EPFL)

Duration: 01.09.2022 -31.08.2025 (36 months) Award: CHF 5 Mio

Lay summary | More information





31.10.24

Personalized Health and Related Technologies (PHRT)

• Strategic focus area of the ETH domain synergizing with SPHN



Translational Technology

A translational technology program that intends to advance innovative technologies pioneered in the ETH Domain for clinical application. It is intended that some of these technologies could form the basis for second-generation platforms.



Personalized health related research projects with direct relevance for the patient. These projects will be carried out in collaboration with and jointly funded by complementary programs such as SPHN. Joint PHRT-SPHN projects ("Driver projects") are funded via this channel.

An educational program on the PhD and postdoc level to train the next generation of scientists in personalized health research.



Platform Centers / Hubs

Platform Centers / Hubs to generate highquality, high-volume individualized molecular profiling data from patients and clinical cohorts. The generated data is intended to directly inform clinical decisions. Second-generation technology platforms will primarily arise from ETH technologies developed in the first phase.

(c)(i)(c)

How can ETH infrastructure, technology & research catalyze the transformation of the healthcare system?

Patient (Data) journey

Bringing patients' clinical and research data together

E.g. Patient owns the data & shares the data with consortium partners via informed consent

Patient

RDMS

LeoMed

Strategic Focus Area Personalized Health and Related Technologies

RESEARCH DATA


E.g. Structured research data generated by SMOC and others is stored, analyzed, and visualized in a secure Research Data Management System.

E.g. Secure data processing infrastructure incl. LeoMed, ALPS etc

E.g. FAIR Data ecosystem

Portal

Entry point for "quick win" analyses and the development of predictive models for national and international clinical researchers




Board

feedback, treatment, relapse, etc, longitudinal patient info is recorded to develop new therapeutic options for patients.

systems.


Wouldn't it be great if we could predict clinical outcomes based on multi-modal data?



Chat GPT 4.0 / DALL-E, October 2024

"A highly detailed and accurate illustration of the cellular surfaceome and lipid rafts"

Personalized Health builds on the combination of clinical and molecular data



J. Montaner et al.. Nat. Rev. Neurol. (2020).

- Clinical samples cannot be regenerated.
- Turning clinical specimens into searchable and reusable digital biobanks would facilitate retrospective and highlypowered studies.
- Integrative analyses drive the discovery of mechanisms and novel targets.

- How can we digitize clinical biospecimens on a multi-modal level?
 - How can we generate the required data layers necessary to predict drug response?

SMC

ETH PHRT

Swiss Multi-Omics Center

INTEGRATED DIGITIZATION OF CLINICAL BIOSPECIMEN COHORTS ON THE MOLECULAR LEVEL

DNA | RNA | Protein | Metabolites | Lipids



Hope for patients with a severe rare disease

ETH zürich News & events ETH Zurich Studies at ETH Zurich Doctorate Research Industry & Knowledge Transfer 0 Campus Hope for patients with a severe rare disease ing the results of multiple molecular analyses, scientists can better diagnose the hereditary disease methylmalonaciduria. There is also hope with regard to therapy. **m**

- Methylmalonic aciduria (MMA) is an inborn error of metabolism with multiple monogenic causes and a poorly understood pathogenesis.
- Physicians have relied mainly on DNA sequencing for genetic diagnosis of Methylmalonic aciduria (MMA).
- This approach has led to repeated instances of the correct diagnosis being overlooked.



Network brings success

nature metabolism

Article

https://doi.org/10.1038/s42255-022-00720-i


0

Integrated multi-omics reveals anaplerotic rewiring in methylmalonyl-CoA mutase deficiency

Received: 11 April 2022	Patrick Forny ^{1,16} , Ximena Bonilla ^{2,16} , David Lamparter ^{3,4,16} , Wenguang Shao ^{4,5,16} , Tanja Plessl ¹ , Caroline Frei ¹ , Anna Bingisser ¹ , Sandra Goetze ^{4,5,6} , Audrey van Drogen ^{4,5} , Keith Harshman ^{3,4} , Patrick G. A. Pedrioli ^{4,5,6,7} , Cedric Howald ³ , Martin Poms ⁸ , Florian Traversi ¹ ,
Accepted: 1 December 2022	
Published online: 26 January 2023	
Check for updates	Céline Bürer ¹ , Sarah Cherkaoui ^{9,10} , Raphael J. Morscher [®] ⁹ , Luke Simmons ¹¹ , Merima Forny ¹ , Ioannis Xenarios ^{4,12} , Ruedi Aebersold ⁷ , Nicola Zamboni ^{4,7} ,
	Gunnar Rätsch @ 2.6.13,14,17 , Emmanouil T. Dermitzakis ^{3,4,15,17}
	Bernd Wollscheid ^{4,5,6,17} , Matthias R. Baumgartner (1) ^{1,17}
	& D. Sean Froese @ ^{1,17}



Multi-dimensional analysis enables new insights into disease biology



 210 patient biopsies were studied in detail on the level of all of the genes (DNA) in the patient's cells, but also the RNA transcripts of these genes and many of the proteins.

 Integrative data analysis led to the development of a diagnostic strategy that correctly diagnosed 84 percent of the patients examined!



New approach not only to MMA therapy

News & views Mechanisms of disease Anaplerosis in action PamelaSara E. Head & Charles P. Venditti Investigation of multi-omic changes and their effects on regulation of metabolic pathways confirm anaplerotic deficiencies in methylmalonic acidaemia, strengthening the need for future therapies aimed at replenishing intermediates of the tricarboxylic acid cycle.

- Moving forward, our new strategy will drastically increase the chances for patients to receive a correct diagnosis and allow the provision of the correct treatment at a much earlier stage.
- The **project was the precursor for the NDS SwissPedHealth**, which aims to increase diagnostic effectiveness, further extend the multi-omics approach to other genetic diseases, and harmonize the continuous clinical data flow.
- Strategy revolutionizes disease/cancer diagnosis, treatment, and management by leveraging state-of-the-art technology, interoperable data, and expertise from diverse fields.

 The long-term objective is to create artificially intelligent, mechanistic disease models that translate patient data into precision diagnosis and treatment.







Aim to align with the parallel ongoing genomics/multi-omics initiatives at the European level



Genome of Switzerland



Swiss fEGA repository









Genome of Switzerland





Swiss Federated Genomics Network



Pilot stage (2024)

 Clinical-grade WGS of 1,000 popula SMSC samples
 kealth 2030

Analysis and characterization of the pilot reference dataset

- Using pilot use cases proposed by the Genome of Europe
 - 1. Lookups of individual variants across the Genome of Europe
 - 2. Providing population distributions for polygenic risk scores
 - 3. Generating reference panels for ancestry-specific imputation




genome center

PHRT "RAPID" Trial

Pharmacoscopy-guided Clinical Standard-of-care in Relapsed/Refractory Acute Myeloid Leukemia (AML), a Randomized Phase-2 Clinical Trial

Pharmacoscopy: Personal image-based drug screening



ETHZÜRICH USZ Universitäts Spital Zürich







PHRT "PROGNOSTICS" Trial

PeRsOnalized theraGNOstics of metaStaTIC proState cancer, a Dose Identification/Escalation Phase Ia/b Clinical Trial

The consortium will test an innovative drug that precisely targets the tumor and emits radiation in its vicinity.



- Does a novel radioligand (161Tb-SibuDAB) improve response compared to standard radioligand therapy (RLT) in patients with progressive metastatic castration-resistant prostate cancer (mCRPC)?
- PSI is enabling the production of 161Tb-SibuDAB (including the radionuclides)
- ClinicalTrials.gov NCT06343038









Acknowledgements SPHN & PHRT

A big "**THANK YOU**" to the PHRT & SPHN "Implementation Team" across Switzerland and all of you being here today!

- Thank you to a new Swiss community of 1000+ researchers, clinicians, IT specialists & patients across Swiss clinical and research institutions.
- Thank you SERI & ETH domain, for a significant investment that enabled us to foster communication & collaboration between the diverse stakeholders in the Swiss healthcare system, driving structural changes and leveraging insights to benefit patients.
- Thanks to this community effort across stakeholders, we can now go full circle beyond scientific publications and translate data insights into new therapeutic choices for the benefit of patients validated in clinical trials.

Thanks to the enormous efforts by SPHN & PHRT boards, committees and office teams Switzerland is being recognized internationally as a driver in developing the

FUTURE OF MEDICINE